What do systematic reviews say?

Mesh vs non‐mesh repair

• Mesh versus non‐mesh for inguinal and femoral hernia repair 2018 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1680 participants
  Low

Gemcitabine plus mitomycin C vs capecitabine plus mitomycin C

It is very uncertain whether gemcitabine plus mitomycin C changes grade 1 ‐ 4 thrombocytopenia compared with capecitabine plus mitomycin C (very low certainty).

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  RR 0.56 [0.29, 1.06]
  1 study · 47 participants
  Very low

Intervention not reported

The intervention probably leads to higher leukopenia** grade 3 or 4 (safety population) (moderate certainty).

• Platinum‐containing regimens for metastatic breast cancer 2017 · Cochrane Headline outcomes only
  RR 1.38
  22 studies · 3176 participants
  Moderate

Heparin prophylaxis vs no prophylaxis

Heparin prophylaxis showed no clear difference in thrombocytopenia compared with no prophylaxis (moderate certainty).

• Parenteral anticoagulation in ambulatory patients with cancer 2017 · Cochrane Headline outcomes only
  RR 0.69 [0.37, 1.27]
  12 studies · 5832 participants
  Moderate

Intervention not reported

The intervention leads to lower grade 3 to 4 neutropenia (high certainty).

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  OR 0.7 [0.53, 0.93]
  3 studies · 968 participants
  High

Intervention not reported

The review found no eligible studies for this question.

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention probably leads to lower grade 3 to 4 neutropenia (moderate certainty).

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1341 participants
  Moderate

Intervention not reported

The review found no eligible studies for this question.

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 1651 participants
  Moderate

Intervention not reported

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 99 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in grade 3 to 4 neutropenia (moderate certainty).

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  OR 1.22 [0.93, 1.61]
  6 studies · 2666 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in grade 3 to 4 neutropenia (moderate certainty).

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  OR 0.97 [0.73, 1.29]
  2 studies · 1187 participants
  Moderate

Oral vs intravenous fluoropyrimidines

Oral may leads to lower grade ≥ 3 neutropenia/granulocytopenia compared with intravenous fluoropyrimidines (low certainty).

• Oral versus intravenous fluoropyrimidines for colorectal cancer 2017 · Cochrane Headline outcomes only
  OR 0.17 [0.15, 0.18]
  29 studies · 11794 participants
  Low

Oral vs intravenous fluoropyrimidines

Oral probably leads to lower grade ≥ 3 neutropenia/granulocytopenia compared with intravenous fluoropyrimidines (moderate certainty).

• Oral versus intravenous fluoropyrimidines for colorectal cancer 2017 · Cochrane Headline outcomes only
  OR 0.14 [0.11, 0.16]
  7 studies · 8087 participants
  Moderate

Idrabiotaparinux vs idraparinux

The review found no eligible studies for this question.

• Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Low molecular weight heparin and idraparinux vs usual care

The review found no eligible studies for this question.

• Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Idraparinux vs usual care

The review found no eligible studies for this question.

• Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Fondaparinux plus vitamin K antagonist vs usual care

The review found no eligible studies for this question.

• Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention leads to lower severe adverse events: neutropenia (high certainty).

• Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase… 2016 · Cochrane Headline outcomes only
  RR 0.48 [0.28, 0.82]
  3 studies · 1799 participants
  High